EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

Neeraj Agarwal, Nobuaki Matsubara, Arun A Azad, Fred Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, Eric Voog, Neal D Shore, Timuçin Çil, Christof Vulsteke iD, Hsiao-Jen Chung und 7 weitere

New England Journal of Medicine · 30.07.2026 · 395 (5) · 427-439

DOI: 10.1056/nejmoa2604126 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 30.07.2026. Verfasst von Neeraj Agarwal und 18 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah, Salt Lake City. Hauptthemen laut MEDLINE: Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols, Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsPoly(ADP-ribose) Polymerase InhibitorsProstatic NeoplasmsNeoplasm Recurrence, LocalAgedAged, 80 and overHumansMaleMiddle AgedBenzamidesDouble-Blind MethodNeoplasm MetastasisNitrilesPhenylthiohydantoinPhthalazinesProgression-Free SurvivalRecombinational DNA RepairTumor BurdenProstateResponse Evaluation Criteria in Solid TumorsAdult

Substanzen

Androgen AntagonistsBenzamidesenzalutamideNitrilesPhenylthiohydantoinPhthalazinesPoly(ADP-ribose) Polymerase Inhibitorstalazoparib

Autor:innen und Institutionen

  • Huntsman Cancer Institute, University of Utah, Salt Lake City.
  • National Cancer Center Hospital East, Chiba, Japan.
  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal.
  • Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona.
  • Hunan Cancer Hospital, Changsha, China.

ORCID-Profile: Christof Vulsteke

Förderung

  • Pfizer

Zitieren

APA

Agarwal, N., Matsubara, N., Azad, A. A., Saad, F., Mateo, J., Jiang, S., Ye, D., Voog, E., Shore, N. D., Çil, T., Vulsteke, C., Chung, H. J., Zschäbitz, S., Laird, A. D., Zhang, X., Nandoskar, P., Chetcuti, S. F., Wang, F., & Fizazi, K. (2026). PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. New England Journal of Medicine, 395(5), 427-439. https://doi.org/10.1056/nejmoa2604126

Vancouver

Agarwal N, Matsubara N, Azad AA, Saad F, Mateo J, Jiang S, et al. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. New England Journal of Medicine. 2026;395(5):427-439. doi:10.1056/nejmoa2604126

BibTeX
@article{Agarwal2026,
  author = {Agarwal, Neeraj and Matsubara, Nobuaki and Azad, Arun A and Saad, Fred and Mateo, Joaquin and Jiang, Shusuan and Ye, Dingwei and Voog, Eric and Shore, Neal D and Çil, Timuçin and Vulsteke, Christof and Chung, Hsiao-Jen and Zschäbitz, Stefanie and Laird, A Douglas and Zhang, Xiaoxi and Nandoskar, Prachi and Chetcuti, Sarah Fenech and Wang, Fong and Fizazi, Karim},
  title = {PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {5},
  pages = {427--439},
  doi = {10.1056/nejmoa2604126}
}
Kostenlos starten →